Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yongyi Zeng

Showing results (191-200 of 196) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 196 results.
Liver Cancer|May 26, 2025
Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 StudyZhaolong Pan, Dongming Liu, Junbo Cao, et al.
The Oncologist|October 24, 2023
Prognoses of Patients Treated With Surgical Therapy Versus Continuation of Local-Plus-Systemic Therapy Following Successful Down-Staging of Intermediate-Advanced Hepatocellular Carcinoma: A Multicenter Real-World StudyJianwei Liu, Xiaodong Zhu, Yangxun Pan, et al.
Alimentary Pharmacology & Therapeutics|June 23, 2023
Effect of different PD-1 inhibitor combination therapies for unresectable intrahepatic cholangiocarcinomaZhengqing Lei, Weihu Ma, Anfeng Si, et al.
Hepatobiliary Surgery and Nutrition|June 11, 2026
Chinese expert consensus on conversion and perioperative therapy of primary liver cancer (2024 edition)Zheng Wang, Huichuan Sun, Jian Zhou, et al.
Bioscience Trends|December 25, 2024
Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition)Haowen Tang, Wenwen Zhang, Junning Cao, et al.
Liver Cancer|October 9, 2025
China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition)Jian Zhou, Huichuan Sun, Zheng Wang, et al.
Pageof 20

Showing results (191-200 of 196) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 196 results.
Liver Cancer|May 26, 2025
Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 StudyZhaolong Pan, Dongming Liu, Junbo Cao, et al.
The Oncologist|October 24, 2023
Prognoses of Patients Treated With Surgical Therapy Versus Continuation of Local-Plus-Systemic Therapy Following Successful Down-Staging of Intermediate-Advanced Hepatocellular Carcinoma: A Multicenter Real-World StudyJianwei Liu, Xiaodong Zhu, Yangxun Pan, et al.
Alimentary Pharmacology & Therapeutics|June 23, 2023
Effect of different PD-1 inhibitor combination therapies for unresectable intrahepatic cholangiocarcinomaZhengqing Lei, Weihu Ma, Anfeng Si, et al.
Hepatobiliary Surgery and Nutrition|June 11, 2026
Chinese expert consensus on conversion and perioperative therapy of primary liver cancer (2024 edition)Zheng Wang, Huichuan Sun, Jian Zhou, et al.
Bioscience Trends|December 25, 2024
Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition)Haowen Tang, Wenwen Zhang, Junning Cao, et al.
Liver Cancer|October 9, 2025
China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition)Jian Zhou, Huichuan Sun, Zheng Wang, et al.
Pageof 20